TheFly.com
Start Free Trial
<
Back to all Breaking News
NVS
11/13/2017 12:11pm
4
Street Research Stories
6
Calendar Events
chevron_right
Novartis canakinumab reduced CV risk by 25% in subgroup of CANTOS trial
Don't miss out!
We read the Wall Street research, SEC filings and press releases so you don't have to.
Sign up for our 14-day free trial to read this story.
Join Now
Learn More
Already have an account?
Sign In Here
Subscription Rates
dynamic_feed
Breaking News
search
Search
menu
Menu
